Navigation Links
Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
Date:11/1/2007

WALTHAM, Mass., Nov. 1 /PRNewswire/ -- Proteon Therapeutics (http://www.proteontherapeutics.com), a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, is presenting tomorrow at the Annual Meeting of the American Society of Nephrology an abstract entitled "Recombinant Human Elastase (PRT-201) Dilates Outflow Veins in a Preclinical Model of Arteriovenous Fistula." Findings to be presented represent an important preclinical demonstration of the potential of PRT-201 to enhance arteriovenous fistula (AVF) surgery outcomes in patients requiring chronic hemodialysis. It is well documented that between 30 and 50 percent of AVFs, the preferred form of vascular access, fail to mature to usable access sites for dialysis patients.

"Vascular access related complications are a major cause of suffering and hospitalization for dialysis patients," said Timothy P. Noyes, the Company's President and CEO. "We believe that PRT-201 could potentially facilitate the creation of more reliable dialysis access sites."

About Vascular Access in Hemodialysis

Patients with end stage kidney disease must undergo periodic external blood filtering by hemodialysis machines in order to remove fluid and metabolic byproducts from their blood. Vascular surgeons prepare patients for hemodialysis by creating access sites in the body that can be connected to hemodialysis machines. These high flow access sites are usually created by connecting an artery to a vein, resulting in a "shunt" of blood from the artery to the vein. There are three main types of chronic hemodialysis access sites: Arteriovenous fistulas are created by connecting veins directly to arteries, arteriovenous grafts are created by connecting veins to arteries with a segment of artificial tubing, and catheters are placed directly in large vein
'/>"/>

SOURCE Proteon Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 27, 2015 Research ... addition of Jain PharmaBiotech,s new report ... their offering. An increasing use ... industries is anticipated. Nanotechnology will be applied ... from formulations for optimal delivery to diagnostic ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) has ... "Neuroprotection - Drugs, Markets and Companies" ... the role of neuroprotection in acute disorders such ... as well as in chronic diseases such as ... of damage to neural tissues are similar in ...
(Date:5/28/2015)... 2015 Natera, Inc., a leader in ... in Ultrasound in Obstetrics & Gynecology ... prenatal test (NIPT) can identify a complete molar ... A study based upon data collected in the ... about 1 in 1,000 pregnancies, although other studies ...
(Date:5/28/2015)... 2015  PDS Biotechnology Corp. announces preliminary data ... HPV-16, has generated strong T-cell responses in pre-cervical ... is treated by surgical removal of lesions however, ... alternative. Results show that it primes and activates ... and kill precancerous and cancerous cells that display ...
Breaking Biology Technology:Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2
... Supports Further ... Clinical Development of tgAAC94, BOSTON and SEATTLE, May ... news release earlier today, entitled,"Targeted Genetics Reports Additional Data From ... 1/2,clinical study of tgAAC94 in patients with inflammatory arthritis. Pervin,Anklesaria, ...
... the increasing,challenges to patent protection and new product ... grow their pipelines.,With the increasing merger and acquisition ... integration of assets to be key in obtaining,value ... Integration,Excellence: What Bio- Pharma Companies Need to Know." ...
... U.S. cancer conference, CHICAGO, May 30 ... field of molecular diagnostics, announced today that data,from ... test,will be presented at the American Society of ... that MammaPrint, a,prognostic test for breast cancer recurrence ...
Cached Biology Technology:Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings 2Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings 3Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence 2MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions 2MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions 3MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions 4
(Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... KINGSTON, R.I. July 23, 2009 News reports ... by large numbers of Humboldt,s or jumbo squid have raised ... As a leading expert on the species who has ... and says the squid,s man-eating reputation is seriously overblown. ...
... study released online on July 22 in the journal ... researchers at Arizona State University and Princeton University show ... our multimodal, egg-headed, tool-using, bipedal, opposing-thumbed selves. ... "stupider" than ants. Humans and animals simply often make ...
... Texas Medical Branch at Galveston have identified women who are ... commonly known as Depo-Provera or the birth control shot. These ... will gain weight and will help physicians to counsel patients ... within the first six months of use, called "early gainers," ...
Cached Biology News:URI researcher sheds light on 'man-eating' squid; finds them timid, nonthreatening 2URI researcher sheds light on 'man-eating' squid; finds them timid, nonthreatening 3Ants more rational than humans 2UTMB study identifies women at risk of gaining excessive weight with injectable birth control 2
... Histone Deacetylase (HDAC) Antibody Sampler Kit ... (HDAC1) Antibody, Catalog #2062, 40 ul Histone ... ul Histone Deacetylase 4 (HDAC4) Antibody, Catalog ... Antibody, Catalog #2082, 40 ul Histone Deacetylase ...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
Request Info...
interferon-related developmental regulator 2...
Biology Products: